Androgen Therapy
Phase 3Small molecule
Androgen Therapy is one of 6 small molecule programs targeting Castration-Sensitive Prostate Carcinoma. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Castration-Sensitive Prostate Carcinoma
#DrugCompanyPhaseTrials
1Erleada
Johnson & JohnsonPhase 3
Taxotere
AAvyxa
Phase 3
Zytiga
Johnson & JohnsonPhase 2
Rayos
RRoxane Laboratories
Phase 2
Antiandrogen Therapy
UUniversity of Washington
Phase 2
Androgen Therapy
AAlliance for Clinical Trials in Oncology
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Androgen Therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details